OpenText process and document management solutions for pharmaceutical & life sciences conference

13 - 14 May 2013, Kassel, Germany.
OpenText solutions for the Pharmaceutical and Life Sciences industries support critical processes where compliant management of all paper and electronic records and documents is essential. You are invited to attend the Comprehensive Process and Document Management Life Science Conference held in Kassel, Germany. Join this conference to learn about the GxP Compliance, Document Management in CMC, Computer System Validation and other topics with the "Ask the Experts" session.

Get an Free Onsite Visit at B. Braun in Melsungen and watch how B. Braun made the switch from EMC Documentum to OpenText Regulated Documents.

OpenText will present for the first time the newest Solutions for Business Process Management "ASSURE for Regulated Documents" on this conference.

Visit this life science event and get an onsite visit at B. Braun in Melsungen (Germany) for free and have an "Ask the Experts" session on the 13th May. The onsite visit includes as well the networking dinner.

Follow this link and register today for the free "Onsite Visit" at B. Braun, B. Braun is one of the world's leading healthcare suppliers. Their four divisions orient their products and services toward different medical fields: hospital, surgery, private practice (medical care and doctors' offices) and extra-corporeal blood treatment.

Registration web link (in German language)

About OpenText
OpenText is the leader in Enterprise Information Management (EIM). EIM enables organizations to grow the business, lower costs of operations, and reduce information governance and security related risks. OpenText focuses on the key drivers of business success to improve business insight, strengthen business impact, accelerate process velocity, address information governance and provide security.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Consuming milk at breakfast lowers blood glucose t…

A change in breakfast routine may provide benefits for the management of type 2 diabetes, according to a new study published in the Journal of Dairy Science. H. Douglas G...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...